1. Home
  2. |Insights
  3. |PODCAST: The Trump Administration’s New Import Duties on Canadian Softwood Lumber – C&M’s First 100 Days Series

PODCAST: The Trump Administration’s New Import Duties on Canadian Softwood Lumber – C&M’s First 100 Days Series

Client Alert | 1 min read | 04.28.17

In the last few days the news has been chock-a-block with headlines about the administration slapping new import duties on softwood lumber from Canada. As part of our First 100 Days series, International Trade Group partner Alex Schaefer sits down to discuss the duties. Alex represents clients contending with U.S. import regulations, including the customs and trade remedies laws.

Discussed in this 6 minute podcast

  • The background of this lumber dispute.
  • The reasons for the new import duties.
  • What the future may hold on the lumber front.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Insights

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  ...